NYSE:GKOS - Glaukos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Glaukos Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.77 -2.09 (-6.77 %) (As of 04/1/2020 04:00 PM ET) Add Compare Today's Range$27.91Now: $28.77▼$30.8850-Day Range$25.53MA: $47.42▼$70.1452-Week Range$23.31Now: $28.77▼$84.65Volume553,339 shsAverage Volume1.59 million shsMarket Capitalization$1.26 billionP/E Ratio110.66Dividend YieldN/ABeta1.7 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.Read More Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS Previous Symbol CUSIPN/A CIK1192448 Webhttp://www.glaukos.com/ Phone949-367-9600Debt Debt-to-Equity Ratio0.11 Current Ratio4.56 Quick Ratio3.82Price-To-Earnings Trailing P/E Ratio110.66 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$236.98 million Price / Sales5.31 Cash Flow$0.14 per share Price / Cash Flow213.09 Book Value$18.50 per share Price / Book1.56Profitability EPS (Most Recent Fiscal Year)($0.10) Net Income$15.42 million Net Margins6.51% Return on Equity-3.74% Return on Assets-2.79%Miscellaneous Employees437 Outstanding Shares43,740,000Market Cap$1.26 billion Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive GKOS News and Ratings via Email Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. GKOS Rates by TradingView Glaukos (NYSE:GKOS) Frequently Asked Questions How has Glaukos' stock been impacted by COVID-19 (Coronavirus)? Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GKOS stock has decreased by 25.5% and is now trading at $28.77. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Glaukos? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Glaukos. When is Glaukos' next earnings date? Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Glaukos. How were Glaukos' earnings last quarter? Glaukos Corp (NYSE:GKOS) posted its earnings results on Thursday, February, 27th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.11. The medical instruments supplier earned $65.85 million during the quarter, compared to analyst estimates of $65.36 million. Glaukos had a negative return on equity of 3.74% and a net margin of 6.51%. The firm's revenue was up 21.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.08 EPS. View Glaukos' earnings history. What guidance has Glaukos issued on next quarter's earnings? Glaukos issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $290-300 million, compared to the consensus revenue estimate of $299 million. What price target have analysts set for GKOS? 9 Wall Street analysts have issued 1 year target prices for Glaukos' shares. Their forecasts range from $36.00 to $71.00. On average, they anticipate Glaukos' stock price to reach $55.75 in the next year. This suggests a possible upside of 93.8% from the stock's current price. View analysts' price targets for Glaukos. What are Wall Street analysts saying about Glaukos stock? Here are some recent quotes from research analysts about Glaukos stock: 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019) 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019) Has Glaukos been receiving favorable news coverage? News stories about GKOS stock have trended very negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Glaukos earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutGlaukos. Who are some of Glaukos' key competitors? Some companies that are related to Glaukos include Globus Medical (GMED), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), NuVasive (NUVA), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Cantel Medical (CMD), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII), Atrion (ATRI), Luminex (LMNX) and Inovio Pharmaceuticals (INO). What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), Caterpillar (CAT), Boeing (BA), Baidu (BIDU), DexCom (DXCM), NVIDIA (NVDA) and QUALCOMM (QCOM). Who are Glaukos' key executives? Glaukos' management team includes the following people: Mr. Thomas William Burns, CEO, Pres & Director (Age 58)Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)Mr. Richard L. Harrison, Advisor (Age 62)Dr. Mory Gharib Ph.D., Co-Founder When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." How do I buy shares of Glaukos? Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $28.77. How big of a company is Glaukos? Glaukos has a market capitalization of $1.26 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe. View additional information about Glaukos. What is Glaukos' official website? The official website for Glaukos is http://www.glaukos.com/. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected] MarketBeat Community Rating for Glaukos (NYSE GKOS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 383 (Vote Outperform)Underperform Votes: 295 (Vote Underperform)Total Votes: 678MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: Different Types of Derivatives
